Ibandronsäure Actavis (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during bone resorption. Inside the cell it disrupts the mevalonate pathway, leading to osteoclast apoptosis and a consequent reduction in bone breakdown.

The dosing regimen for Ibandronsäure Actavis is determined by the prescribing clinician based on the patient’s condition, renal function and other clinical factors. It is administered as an intravenous infusion by a qualified healthcare professional.

Safety data for ibandronic acid during pregnancy and lactation are limited. The product is generally avoided in pregnant or nursing women unless the potential therapeutic benefit outweighs the possible risk to the fetus or infant.

To request Ibandronsäure Actavis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Ibandronsäure Actavis is an intravenous bisphosphonate similar to zoledronic acid but is typically given less frequently (e.g., once yearly for osteoporosis). Its potency in inhibiting bone resorption is comparable, while the safety profile, especially regarding acute‑phase reactions, may differ slightly between agents.

The product must be stored refrigerated at 2 °C to 8 °C, protected from light, and must never be frozen or shaken. Prior to use, inspect the solution for particulate matter and ensure it is at room temperature if required by the administration protocol.

Ibandronsäure Actavis is supplied as a sterile intravenous injection solution. It is administered by a healthcare professional as an infusion over a prescribed period, usually lasting several minutes to an hour, depending on the dosing schedule.

Serious adverse events include osteonecrosis of the jaw, atypical femur fractures, and severe renal impairment. Patients should be monitored for signs of jaw pain, unusual thigh or groin pain, and changes in kidney function throughout treatment.

Ibandronsäure Actavis is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid or any formulation component, and in those with active dental or jaw infections that could predispose to osteonecrosis.